On, two relapsed just before consolidation and 3 received alternative consolidation remedy [azacitidine (n=2) and clofarabine (n=1)]. Fifteen individuals, corresponding to 29 with the sufferers aged much less than 70 years, defined by age as eligible for transplantation, underwent allogeneic stem cell transplantation, 11 in 1st remission (9 in complete remission, 2 in partial remission), and 4 soon after induction failure.Thirty-five on the 48 responders subsequently relapsed, including 29 of the 38 patients who had accomplished a CR, having a 1-year cumulative incidence of relapse of 64.6 (95 CI: 50.7-78.4). The median duration of response was 6 months, even though that of CR was 6.two months. Amongst the 11 sufferers allografted in initially remission, six relapsed, three had an early death and two had been alive in comprehensive remission soon after 12 and 14 months. 3 with the 4 sufferers allografted right after induction failure died, two from relapse and a single from graft-versus-host disease, and one particular was nonetheless alive just after 8 months. Seventy-seven individuals died, 16 of them within 90 days of treatment onset (early death) top to an early death price of 20.8 (95 CI: 12.4-31.5 ). The median overall survival was 8.2 months (95 CI: 7.15-10.5), and 1- and 2-Table 1. Primary baseline qualities from the individuals in the 3 cohorts.Variables n.Age [IQR] Gender Female Male WHO 2008 diagnosis RAEB-2 AML FAB diagnosis RAEB RAEB-t AML Performance Status 0 1 two Cytogenetics Failure (5q by FISH) Isolated del(5q) del(5q) +1 abnormality ComplexOverall N=82Cohort 1 LEN 10/DNR 45 N=31 n.65.2 [59.four;73.0] 15 16 11 20 11 7 13 13 11 five two two two 25 48 52 35 65 35 23 42 45 38 17 six 6 six 82Cohort 2 LEN 10/DNR 60 N=32 n.66.7 [54.six;71.9] 17 15 six 26 6 five 21 five 16 three 1 two five 24 53 47 19 81 19 16 65 21 67 12 three six 16 75Cohort three LEN 25/DNR 60 N=19 n.66.1 [61;68.8] 8 11 four 15 3 10 6 2 9 3 0 4 2 13 42 58 21 79 16 53 31 14 64 22 0 21 10 6966.1 [58.two;71.8] 40 42 21 61 20 22 40 20 36 10 three 8 9 62 49 51 26 74 24 27 49 30 55 15 four ten 11 75LEN: lenalidomide (dose in mg/day); DNR: daunorubicin (dose in mg/m2/day); WHO: World Overall health Organization; RAEB: refractory anemia with excess blasts; FAB: French American British; RAEB-t: refractory anemia with excess blasts in transformation; AML: acute myeloid leukemia; FISH: fluorescence in situ hybridization.ABCFigure two. Outcome inside the distinct treatment cohorts. (A) All round survival, (B) event-free survival, (C) cumulative incidence of relapse.haematologica | 2017; 102(four)L. Ades et al.year all round survival rates have been 30.5 (95 CI: 222.three) and 13.4 (95 CI: 7.7-23.2), respectively. The median event-free survival was 5.2,5-Dihydroxyterephthalic acid Price 7 months (95 CI: 4.1-Cyclopentyl-1h-1,2,4-triazole Chemscene 4-7.PMID:23074147 two). No distinction in outcome was observed among treatment cohorts for cumulative incidence of relapse, event-free survival or overall survival (Figure two). When patients have been censored in the time of transplantation, the median overall survival was 7.eight months (95 CI:6.7-9.four), and 1- and 2-year general survival rates were 27.six (95 CI: 18.6-41) and eight.six (95 CI: 3.8-19.7), respectively. The median event-free survival was 4.8 months (95 CI: four.3-6.6) (Figure 3). Among individuals who did not acquire an allograft, only 16 have been alive at 1 year, and five at 2 years.Prognostic variables for response and all round survivalTables two and 3 summarize prognostic factors for CR and overall survival, respectively. The CR rate was considerably reduced amongst AML patients (like these with AML/RAEB-t) (40 ) than a.